Converging lines of evidence implicate abnormalities in the kynurenine pathway (KP) of tryptophan degradation in schizophrenia.
1-4 Increased concentrations of the KP metabolites kynurenine and kynurenic acid (KYNA) have been found in postmortem brain tissue
1,2 and cerebrospinal fluid
3,4 of individuals with schizophrenia. Moreover, genetic variants in KP enzymes have been linked to psychotic symptoms, cognitive dysfunctions, and abnormal levels of KYNA.
5-7 In the brain, KYNA can act as an antagonist at
N-methyl-d-aspartate and α7 nicotinic receptors, both of which have been closely associated with schizophrenia.
8 At higher concentrations, KYNA can also be neuroprotective in conditions of excitotoxicity.
9-11 However, the clinical significance of kynurenergic abnormalities in patients with schizophrenia remains unclear.